(DRIO) DarioHealth - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US23725P2092

DRIO: Digital, Therapeutics, Devices, Coaching

DarioHealth Corp (NASDAQ:DRIO) is a digital health company operating in the United States, Canada, the European Union, Australia, and New Zealand. The company specializes in delivering personalized digital therapeutics and dynamic interventions through its platform, leveraging data analytics and one-on-one coaching. Its solutions address chronic conditions such as diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. The product portfolio includes Dario Evolve, a metabolic health solution for diabetes, pre-diabetes, hypertension, and weight management; Dario Move, targeting common musculoskeletal conditions; Dario Elevate, a behavioral health solution optimizing evidence-based care access; and Dario One, a comprehensive suite for chronic condition management. Additionally, the company offers native devices, including glucose meters, blood pressure cuffs, digital scales, and biofeedback sensors, alongside live coaching services. DarioHealth Corp, formerly known as LabStyle Innovations Corp, was incorporated in 2011 and is headquartered in New York, New York.

Based on and , the 3-month forecast for DRIO indicates potential volatility. The stock is currently trading at $0.73, with a 20-day SMA of $0.68 and a 50-day SMA of $0.72, suggesting near-term stability. However, the 200-day SMA of $0.95 indicates downside pressure. The ATR of 0.12 signals moderate volatility. Fundamentally, the market cap of $26.71M and P/S ratio of 1.16 reflect its small-cap status and revenue multiple. The negative RoE of -59.16% highlights profitability challenges. Overall, the stock may face headwinds but could stabilize near current levels if revenue growth accelerates.

Additional Sources for DRIO Stock

DRIO Stock Overview

Market Cap in USD 27m
Sector Healthcare
Industry Health Information Services
GiC Sub-Industry Health Care Equipment
IPO / Inception 2014-10-06

DRIO Stock Ratings

Growth 5y -89.9%
Fundamental -40.4%
Dividend 0.0%
Rel. Strength Industry -59.9
Analysts 5/5
Fair Price Momentum 0.39 USD
Fair Price DCF -

DRIO Dividends

No Dividends Paid

DRIO Growth Ratios

Growth Correlation 3m -55.6%
Growth Correlation 12m -90.3%
Growth Correlation 5y -89.7%
CAGR 5y -32.40%
CAGR/Max DD 5y -0.33
Sharpe Ratio 12m -0.03
Alpha -69.88
Beta 1.41
Volatility 90.12%
Current Volume 79.3k
Average Volume 20d 181.6k
What is the price of DRIO stocks?
As of March 14, 2025, the stock is trading at USD 0.65 with a total of 79,328 shares traded.
Over the past week, the price has changed by -10.69%, over one month by -0.23%, over three months by -11.40% and over the past year by -59.98%.
Is DarioHealth a good stock to buy?
Probably not. Based on ValueRay Fundamental Analyses, DarioHealth (NASDAQ:DRIO) is currently (March 2025) not a good stock to buy. It has a ValueRay Fundamental Rating of -40.43 and therefor a somewhat negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of DRIO as of March 2025 is 0.39. This means that DRIO is currently overvalued and has a potential downside of -40%.
Is DRIO a buy, sell or hold?
DarioHealth has received a consensus analysts rating of 5.00. Therefor, it is recommend to buy DRIO.
  • Strong Buy: 3
  • Buy: 0
  • Hold: 0
  • Sell: 0
  • Strong Sell: 0
What are the forecast for DRIO stock price target?
According to ValueRays Forecast Model, DRIO DarioHealth will be worth about 0.4 in March 2026. The stock is currently trading at 0.65. This means that the stock has a potential downside of -33.85%.
Issuer Forecast Upside
Wallstreet Target Price 3.2 387.7%
Analysts Target Price 3.5 438.5%
ValueRay Target Price 0.4 -33.8%